These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 9553809)
1. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Soslow RA; Shen PU; Chung MH; Isacson C Int J Gynecol Pathol; 1998 Apr; 17(2):129-34. PubMed ID: 9553809 [TBL] [Abstract][Full Text] [Related]
2. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476 [TBL] [Abstract][Full Text] [Related]
3. [Interaction between p53 and MDM2 in human lung cancer cells]. Rybárová S; Hodorová I; Vecanová J; Muri J; Mihalik J Klin Onkol; 2014; 27(1):33-7. PubMed ID: 24635435 [TBL] [Abstract][Full Text] [Related]
4. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas. Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188 [TBL] [Abstract][Full Text] [Related]
5. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128 [TBL] [Abstract][Full Text] [Related]
6. Analysis of the immunoreactivity of three anti-p53 antibodies and estimation of the relations between p53 status and MDM2 protein expression in ovarian carcinomas. Harlozińska A; Bar J; Montenarh M Anticancer Res; 2000; 20(2A):1049-56. PubMed ID: 10810396 [TBL] [Abstract][Full Text] [Related]
7. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370 [TBL] [Abstract][Full Text] [Related]
8. p53 protein and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type. An immunohistochemical examination on paraffin sections. Nielsen AL; Nyholm HC Am J Clin Pathol; 1994 Jul; 102(1):76-9. PubMed ID: 7913577 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803 [TBL] [Abstract][Full Text] [Related]
10. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Li C; Zota V; Woda BA; Rock KL; Fraire AE; Jiang Z; Lu D; Xu B; Dresser K; Lutman CV; Fischer AH Mod Pathol; 2007 Dec; 20(12):1263-8. PubMed ID: 17885673 [TBL] [Abstract][Full Text] [Related]
11. Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer. Maeda K; Tsuda H; Hashiguchi Y; Yamamoto K; Inoue T; Ishiko O; Ogita S Hum Pathol; 2002 Apr; 33(4):386-91. PubMed ID: 12055672 [TBL] [Abstract][Full Text] [Related]
13. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Alvarez T; Miller E; Duska L; Oliva E Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas. Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692 [TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in squamous cell carcinomas of lung. Xue Q; Sano T; Kashiwabara K; Oyama T; Nakajima T Jpn J Cancer Res; 2001 Mar; 92(3):285-92. PubMed ID: 11267938 [TBL] [Abstract][Full Text] [Related]
16. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of Mdm2 and p53 in penile verrucous carcinoma. Ouban A; Dellis J; Salup R; Morgan M Ann Clin Lab Sci; 2003; 33(1):101-6. PubMed ID: 12661905 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors. Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663 [TBL] [Abstract][Full Text] [Related]
19. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors. Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591 [TBL] [Abstract][Full Text] [Related]
20. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Sherman ME; Bur ME; Kurman RJ Hum Pathol; 1995 Nov; 26(11):1268-74. PubMed ID: 7590703 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]